|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,470.00 KRW | +4.59% |
|
+18.91% | -19.79% |
| 12-09 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 25-06-12 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Main competitors
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 1.65x | - | 16.07x | 87.76M | ||
| -.--% | -.--% | -223.46x | 23.87x | 15.7x | -283.06x | -202.06x | 46.43B | ||
| 0.91% | 0.92% | 23.21x | 2.9x | 2.11x | 12.07x | 14.61x | 25.88B | ||
| 4.83% | 4.91% | 18.14x | 1.26x | 1.39x | 7.87x | 14.45x | 7.76B | ||
| 0.96% | 1.03% | 51.92x | 11.31x | 9.61x | 33.11x | 41.08x | 3.39B | ||
| -.--% | -.--% | -55.93x | - | - | - | - | 2.13B | ||
| 1.45% | 1.88% | 35.33x | 1.93x | 1.79x | 13.65x | 21.55x | 1.99B | ||
| 0.79% | 1.36% | 31.22x | 1.89x | 1.21x | 9.58x | 13.96x | 1.84B | ||
| 0.13% | 0.12% | 81.15x | 14.58x | 16.89x | 41.71x | 56.87x | 1.46B | ||
| 3.6% | 3.6% | 34.82x | 1.42x | 0.83x | 6.85x | 23.29x | 1.21B | ||
| 1.82% | 2.12% | 45.98x | 15.11x | - | - | - | 1.01B | ||
| 0.34% | 0.4% | 28.85x | 2.17x | - | - | - | 892M | ||
| 3.48% | 3.9% | 17.87x | 1.03x | - | - | - | 853M | ||
| 3.72% | 4.38% | 30.17x | 1.17x | 1.38x | 6.61x | 11.54x | 574M | ||
| Average | 1.69% | 1.89% | 9.17x | 6.55x | 5.25x | -16.85x | 1.14x | 6.82B | |
| Weighted average by Cap. | 0.84% | 0.89% | -96.23x | 13.72x | 9.48x | -138.48x | -94.49x |
- Stock Market
- Stocks
- A340450 Stock
- Sector GC Genome Corporation
- Sector dividends
Select your edition
All financial news and data tailored to specific country editions
















